Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TVTX | Common Stock | Award | $0 | +97.5K | +65.95% | $0.00 | 245K | Jan 31, 2023 | Direct | F1 |
transaction | TVTX | Common Stock | Sale | -$182K | -8.2K | -3.34% | $22.25 | 237K | Feb 1, 2023 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TVTX | Employee stock option (right to buy) | Award | $0 | +260K | $0.00 | 260K | Jan 31, 2023 | Common Stock | 260K | $22.40 | Direct | F3 | |
transaction | TVTX | Performance-based restricted stock units | Award | $0 | +32.5K | $0.00 | 32.5K | Jan 31, 2023 | Common Stock | 32.5K | Direct | F1, F4 |
Id | Content |
---|---|
F1 | Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. |
F2 | The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. |
F3 | One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. |
F4 | This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date. |